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Abstract
Background: PEARLS, a large scale trial of antiretroviral therapy (ART) for HIV (n=1,571, 9 countries, 4 continents), found
that a once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC), but not a once-daily non-nucleoside reverse
transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF), had inferior efficacy
compared to a standard of care twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV). The present study examined non-
adherence in PEARLS.
Methods: Outcomes: non-adherence assessed by pill count and by self-report, and time to treatment failure. Longitudinal
predictors: regimen, quality of life (general health perceptions = QOL-health, mental health = QOL-mental health), social
support, substance use, binge drinking, and sexual behaviors. ‘‘Life-Steps’’ adherence counseling was provided.
Results: In both pill-count and self-report multivariable models, both once-a-day regimens had lower levels of non-
adherence than the twice-a-day standard of care regimen; although these associations attenuated with time in the self-
report model. In both multivariable models, hard-drug use was associated with non-adherence, living in Africa and better
QOL-health were associated with less non-adherence. According to pill-count, unprotected sex was associated with non-
adherence. According to self-report, soft-drug use was associated with non-adherence and living in Asia was associated with
less non-adherence. Both pill-count (HR=1.55, 95% CI: 1.15, 2.09, p,.01) and self-report (HR=1.13, 95% CI: 1.08, 1.13, p,
.01) non-adherence were significant predictors of treatment failure over 72 weeks. In multivariable models (including pill-
count or self-report nonadherence), worse QOL-health, age group (younger), and region were also significant predictors of
treatment failure.
Conclusion: In the context of a large, multi-national, multi-continent, clinical trial there were variations in adherence over
time, with more simplified regimens generally being associated with better adherence. Additionally, variables such as QOL-
health, regimen, drug-use, and region play a role. Self-report and pill-count adherence, as well as additional psychosocial
variables, such QOL-health, age, and region, were, in turn, associated with treatment failure.
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Background
Antiretroviral therapy is increasingly available in diverse parts of
the world [1], with many high-prevalence settings providing
antiretroviral therapy for those who meet country-specific criteria.
High levels of sustained life-long adherence are required for the
successful treatment of HIV, which in turn, can prevent HIV
progression. Additionally, wide-scale successful treatment for HIV
may decrease HIV incidence in endemic settings, as it has been
shown that early HIV treatment can prevent HIV transmission in
serodiscordant couples [2].
Although adherence in resource poor settings may actually be
equal to or better than in North American settings [3–5] in 2006,
12 studies from Africa were available for a meta-analysis, which
suggested an estimate of 77% of populations achieving adequate
levels of adherence [3]. Accordingly, at that time, there was a
significant minority of individuals not achieving optimal adher-
ence. Several qualitative and quantitative studies have examined
factors related to non-adherence in diverse settings, finding
associations with variables such as social supports, side effects,
lack of/inadequate counseling, stigma by healthcare workers in
Tanzania [6]; socio-economic factors, patient/family variables,
healthcare systems in Africa [7]; depression and negative attitudes
about antiretroviral therapy (ART) in Haiti [8]; younger age,
greater pill burden, higher number of doses per day, race, protease
inhibitor (PI)-based regimens in a large scale international trial [9];
stigma to self or family, mental health, economic problems, drug
use in China [10]; and non-disclosure of HIV status, female sex,
being illiterate, side effects, being on ART for fewer than 2 years,
alcohol use, travel time, and lack of knowledge and negative
perceptions about ART in Nepal [11].
The Prospective Evaluation of Antiretrovirals in Resource
Limited Settings (PEARLS) study (ACTG5175) [12] was a large-
scale, randomized clinical non-inferiority trial studying 1,571
HIV-infected individuals from 9 countries and 4 continents
(34.7% Africa, 29.5% Latin America/Carribean, 22.6% Asia,
and 13.3% United States) with the goal of understanding if
simplified regimens (once daily) could perform as well as a
standard of care twice-daily regimen. The primary findings were
that a non-nucleoside reverse transcriptase inhibitor/nucleoside
reverse transcriptase inhibitor (NNRTI/NRTIs) regimen, consist-
ing of efavirenz plus co-formulated emtricitabine-tenofovir-DF
(EFV+FTC/TDF), for which all components were dosed once
daily at the same time, had similar efficacy to a standard of care
NNRTI/NRTIs regimen consisting of efavirenz plus co-formulated
lamivudine-zidovudine, (EFV+3TC/ZDV), where the 3TC/ADV
are NRTI components taken twice daily, but that a protease-
inhibitor (PI) regimen of atazanavir plus didanosine-EC and
emtricitabine (ATV+DDI+FTC), in which all components were
dosed once daily, but the DDI and ATV components were at
different times, was inferior to the standard of care regimen. This
study contained a brief psychosocial assessment battery, allowingfor
a longitudinal examination of whether the regimens in which all
components were dosed once daily (EFV+FTC/TDF and AVT+
DDI+FTC) would have lower non-adherence than the standard of
care regimen that requires twice a day dosing of the NRTI
components, and whether additional predictors of adherence would
be relevant in a diverse international cohort of individuals starting
ART.
Adherence in ACTG A5175/PEARLS Study
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Details of the overall study design can be found both on
clinicaltrials.gov NCT00084136 and in the primary outcome
paper [12]. Study sites were as follows: Instituto de Pesquisa
Clinica Evandro Chagas, Rio de Janeiro, Brazil; Hospital Nossa
Senhora da Conceicao-GHC, Porto Alegre, Brazil; Les Centres
GHESKIO, Port-au-Prince, Haiti; YRG Centre for AIDS
Research & Education, Chennai, India; National AIDS Research
Institute, Pune, India; College of Medicine Clinical Research Site,
Blantyre, Malawi; Kamuzu Central Hospital, Lilongwe, Malawi;
Asociacion Civil Impacta Salud y Educacion - Miraflores and San
Miguel Clinical Research Site, Lima, Peru; Durban Adult HIV
Clinical Research Site, Durban, South Africa; University of
Witwaterself-reportand Clinical HIV Research Unit, Johannes-
burg, South Africa; Research Institute for Health Sciences, Chiang
Mai, Thailand; and Parirenyatwa Hospital Clinical Research
Center, Harare, Zimbabwe. All ACTG sites in the United States
were also eligible to enroll participants. Each individual site’s own
IRB or equivalent organization approved this study. Enrollment in
the US was limited to no more than 18% of total; the remaining
enrollment was distributed equally across the international sites
with an option for international sites to request additional
enrollment once their initial quota of 100 participants was filled.
Participants gave written informed consent to participate in this
study.
To be included in the study, participants needed to be at least
18 years old, have documented HIV-1 infection, have CD4+
lymphocytes below 300 cells/mm
3 and have not had ART
previously (i.e. no more than 7 days of cumulative antiretroviral
therapy prior to study entry, with exception of ZDV or single dose
nevirapine for pMTCT use). Exclusion criteria generally were if
any of the medication regimens was medically contra-indicated.
Women of reproductive potential who were non-pregnant and, if
participating in sexual activity that could lead to pregnancy,
agreed to use contraception (two forms if taking EFV). Participants
were randomized 1:1:1 to an open-label regimen of efavirenz
600 mg daily plus co-formulated lamivudine-zidovudine 150mg/
300 mg twice daily (EFV+3TC-ZDV); or atazanavir 400 mg once
daily with food, plus didanosine-EC 400 mg once daily taken on
an empty stomach 1 hour before or 2 hours after the atazanavir
dose, plus emtricitabine 200 mg once daily (ATV+DDI+FTC); or
efavirenz 600 mg once daily plus co-formulated emtricitabine-
tenofovir-DF 200 mg/300 mg once daily (EFV+FTC-TDF).
Participant flow has been described previously [12]. In brief,
1571 participants were randomized, and 99% of expected study
visits were completed. Although the parent trial continued follow-
up for participants who failed the first antiretroviral regimen, the
present analysis only included data up to regimen failure, with a
maximum of 72 weeks, which was the median time point for when
the Data Safety Monitoring Board recommended stopping the
ATV+DDI+FTC arm due to inferiority.
Measures
Participants completed an interviewer-administered adherence
questionnaire (ACTG QOL0061) and pill counts at every study
visit which yielded a non-adherence self-report score and a non-
adherent pill-count categorization. These were at weeks 2, 4, 8, 12,
16, 20, 24, 32, 40, 48 since start of regimen and every 8 weeks
through end of follow up. A longer psychosocial interview (ACTG
QOL0060) was administered at entry, and weeks 16, 32, and 48
since start of regimen and every 48 weeks through end of follow
up. At all sites, self-report measures were translated and back-
translated to maximize accuracy, and administered in a face to
face interview by study nurses in the local language. These
measures are described below.
Adherence questionnaire. The adherence questionnaire
started with a grid whereby each study drug was listed with the
number of doses prescribed per day filled in by study staff.
Participant would answer the number or prescribed doses missed
for ‘‘yesterday’’, ‘‘2 days ago’’, ‘‘3 days ago’’ and ‘‘the past two
weeks’’. They were then asked a series of questions including when
they last missed medications (within past week, 1–2 weeks ago, 2–4
weeks ago, 1–3 months ago, more than three months ago, or never
missed/n.a.), how many days they had missed taking all of their
doses during the past four days (none, one day, two days, three
days, four days), and whether they missed any medications over
the past weekend (yes/no for Saturday OR Sunday). These 7
questions were scored such that they constituted a non-adherence
score, as described in the data analysis section below. Similar self-
report questions with different recall periods have been used in
adherence assessment [3,5,9] and intervention [13] studies in
diverse settings such as these.
Additionally, participants were asked about potential reasons for
non-adherence. This involved a checklist for ‘‘never’’, ‘‘rarely’’
‘‘sometimes’’ and ‘‘often’’ and had 24 potential reasons for non-
adherence such as ‘‘forgot’’, ‘‘side effects’’ ‘‘transportation
problems getting to the clinic’’, ‘‘lost pills’’ which were generated
from the study sites and using items from prior ACTG trials [14].
The most frequently reported reasons are described.
Pill Count. At each study visit, participants were instructed to
bring any remaining pills to the clinic for a pill count. Study nurses
counted pills expected which yielded a binomial pill count non-
adherence score (missed any pills versus did not miss any pills). If
participants forgot their medicines, these data were coded as
missing.
Psychosocial Interview. The psychosocial interview includ-
ed a modified version [15] of the ACTG SF-21 [16]. To simplify
the analyses, and based on prior adherence research, only the
general health perceptions and mental health subscales were
included. To aid interpretation, this was scaled on to 1–10. We
also included one ACTG question about general satisfaction with
social support [14,15,17]; which asked about overall satisfaction
with social support from friends and families, ranging from 0 (very
dissatisfied) to 3 (Very satisfied). For substance use, there was a
frequency question about binge drinking, asking how often
participants drank 5 or more drinks of alcohol in the past month,
ranging from never (0), to daily (6), a series of yes/no questions for
various hard drugs (e.g. cocaine, heroin) and marijuana (consid-
ered soft drug use), followed by the frequency question for the
substance used most. Lastly, there were questions about sexual
behaviors in the past month, which yielded a variable indicating
whether or not participants reported any HIV sexual transmission
risk behavior in the past week.
Treatment Failure. Treatment failure was defined accord-
ing to ACTG protocol [12]. Briefly, it was defined as two
successive measurements of plasma HIV-1 RNA.=1000 copies/mL
with the first measurement at the week 16 visit or later, disease
progression at the week 12 visit or later, or death, regardless of study
treatment history or status (intention-to-treat).
Data Analysis
For the self-report non-adherence score, we followed the
methodology of Reynolds et al. (2007) [18] and performed
principal component (PC) analysis using the adherence questions
described above to construct a non-adherence factor, approxi-
mating a latent variable. This PC analysis was conducted for each
visit separately. We retained one PC because for each visit, with
Adherence in ACTG A5175/PEARLS Study
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than 1 [19], and the results of a screen test also suggested that only
the first component was meaningful [20]. Additionally, the
majority (.50%) of the variance was explained by the first PC
for each visit.
Overall frequencies for categorical variables and means for
continuous measures were calculated. Additionally, reasons for
non-adherence (among those who reported being non-adherent)
were described using frequencies at the first visit after initiation
(week 2). Because three participants did not complete a baseline
questionnaire, they were not included in the baseline summary
measures, resulting in an analytic sample size of 1,568.
For risk factors of non-adherence over time, unadjusted mixed-
effects regressions were calculated using PROC GLIMMIX (for
missed pills) and PROC MIXED (for non-adherence PC score) in
SAS v. 9.3. All models included a random intercept with an
unstructured covariance, and all models included "month of follow
up" as a main effect. The effect of treatment condition on change
in non-adherence was examined by including the treatment by
time interaction term in both models. Factors associated with non-
adherence over time at p=0.10 were included in multivariable,
adjusted regression models. Mixed-effects regressions allow for
unbalanced and missing data; however, because there was no data
on psychosocial variables at certain measurement occasions by
design (i.e. some variables assessed every weeks and others every 4
months), we performed ‘‘last observation carried forward’’ on
these measures so that the these measurement occasions could be
included – as a result data from all 1,571 participants contributed
to the analysis.
Finally, in order to examine risk factors for week to treatment
failure, unadjusted Cox proportional hazard regressions were
used. All factors associated with week to treatment failure at
p=0.10 were included in adjusted, multivariable Cox Propor-
tional Hazard (PH) regressions. Additionally, treatment condition
was included but not reported in this analysis, as treatment effects
have been reported previously [12]. Cox regressions require
complete-case data analysis. Because the psychosocial risk factors
were not measured at every measurement occasion by design, we
again performed ‘‘last observation carried forward’’ on these
measures. The analytic sample for factors associated with
treatment failure was 1,571. However, a complete-case analysis
was performed for unadjusted and adjusted regressions.
Results
Demographic variables and baseline mean and standard
deviation scores are presented in Table 1. At initiation (week 2),
16.0% (N=187) of participants missed at least one pill via pill
count (13.8%, 14.8%, and 19.5% for the once-daily PI-based
regimen, once-daily NNRTI-based regimen, and twice-daily
standard of care regimen, respectively). According to the relevant
self-report item 11.5% (N=174) of participants reported having
missed at least one pill in the past 2 weeks (8.4%, 11.0%, and 15.1%
for the once-daily PI-based regimen, once-daily NNRTI-based
regimen, and twice-daily standard of care regimen, respectively).
Reasons for non-adherence, initiation (week 2)
Among those who reported missing any doses of any study-
prescribed medication in the past 2 weeks at initiation, the most
common reasons endorsed were forgetting to take pills (37.4%)
and to avoid side effects (33.3%). Additionally, more than 10%
endorsed the following reasons for non-adherence: bad events
from pills (12.6%), did not understand the regimen (11.5%), travel
away from home (10.9%), and other illness got in the way (10.3%).
Table 1. Baseline Participant Characteristics.
Overall (N=1568)
Categorical Variables
Age
,25 135 (8.6)
25–,30 298 (19.0)
30–,35 371 (23.7)
35–,40 317 (20.2)
40–,45 227 (14.5)
.=45 220 (14.0)
Sex
Female 739 (47.1)
Male 829 (52.9)
Region
Latin America/Caribbean 464 (29.6)
Asia 355 (22.6)
Africa 540 (34.4)
United States 209 (13.3)
Binge Alcohol Use
At least weekly 108 (6.9)
Less than weekly 1455 (93.1)
Soft Drug Use, past month
Yes 48 (3.1)
No 1501 (96.9)
Hard Drug Use, past month
Yes 20 (1.3)
No 1530 (98.7)
Any Unprotected Sex, past month
Yes 68 (4.6)
No 1402 (95.4)
Satisfaction with Social Support
Very satisfied 1019 (65.4)
Somewhat satisfied 375 (24.1)
Very/somewhat dissatisfied 165 (10.6)
Continuous Measures Mean (SD)
QOL Subscales (0–10), mean (SD)
QOL_health 5.99 (2.45)
QOL_mental 5.71 (1.31)
Categorical Measures N (%)
Treatment
Once daily PI+ NRTIs: ATV+DDI+FTC 524 (33.4)
Once daily NNRTI + NRTsI: EFV+FTC- TDF 525 (33.5)
Standard of care: 519 (33.1)
EFV+3TC-ZDV
Table Legend:
QOL_health: general health perceptions.
QOL_mental: mental health.
Treatment: Once daily protease inhibitor + nucleoside reverse transcriptase
inhibitors: atazanavir + didanosine-EC and emtricitabine.
Treatment: Once daily non-nucleoside reverse transcriptase inhibitor +
nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated
emtricitabine-tenofovir-DF.
Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.
doi:10.1371/journal.pone.0104178.t001
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ART with family or friends, religious beliefs, ran out of pills, tired
of taking so many pills, pills got damaged, too ill to pick up pills, or
pills were stolen.
Longitudinal models of non-adherence: Weeks 2 through
72
Bivariate association with time. Pill count non-adherence
increased over time (p,0.01); however, there was no significant
change in self-report non-adherence over time (p=0.23) (Table 2).
Bivariate predictors of non-adherence Weeks 2 through
72. Table 2 presents main effects bivariate predictors of self-
report and pill count non-adherence. For both pill-count and self-
report, both once daily regimens were associated with lower levels
of non-adherence than the twice-daily standard of care regimen.
For self-report only, however, the main effect for time was
qualified by a significant interaction (p=0.01). Specifically, the
associations between the once-daily NNRTI/NRTIs regimen
(EFV+FTC/TDF) and the PI-based regimen (ATV+DDI+FTC)
and self-report non-adherence was attenuated over follow up when
compared to the standard of care regimen. For example, at month
1, the once-daily PI-based regimen (Est.=20.27, p,0.01) was
significantly associated with lower non-adherence than the
standard of care regimen. However, by month 10, the once-daily
PI-based regimen (Est.=20.09, p=0.11) was no longer associated
with non-adherence when compared to the standard of care
regimen.
For both pill-count and self-report non-adherence, better QOL
general health perceptions and female sex were also associated
with lower likelihood of non-adherence. In both pill-count and
self-report, region was a significant predictor of non-adherence,
with Africa and Asia having lower levels of non-adherence than
the U.S. referent group, and for self-report, Latin-America having
lower levels of non-adherence than the U.S. Soft and hard drug
use and any unprotected sex were associated with higher non-
adherence for both outcomes. For just the pill-count non-
adherence indicator, binge alcohol use was associated with higher
levels of non-adherence. Better QOL mental health and more
satisfaction with social support were associated with lower self-
report non-adherence.
Multivariable models of non-adherence from weeks 2
through 72 (Table 3). Per the plan for selecting variables from
the bivariate models (via meeting the criterion of having a p value
of ,0.10), both multivariable models (pill count and self-report)
included month of follow up, QOL-health subscale, treatment
regimen, sex, region, binge alcohol use, soft drug use, hard drug
use, and any unprotected sex as potential risk factors. The self-
report model also included QOL-mental health and satisfaction
with social support.
In both self-report non-adherence and pill-count non-adherence
models, both once-daily treatment regimens were associated with
lower levels of non-adherence. Additionally, QOL general health
perceptions and living in Africa (compared to the U.S.) were
associated with lower non-adherence with both indicators of non-
adherence. Hard-drug use was associated with higher non-
adherence for both indicators of non-adherence.
For just the pill-count model, any unprotected sex in the past
month was associated with higher non-adherence.
For just the self-report model, QOL-mental health and female
sex were associated with lower non-adherence, and soft-drug use
was associated with higher non-adherence.
Additionally, for self-report only, there was an interaction for
the effect of treatment regimen with time on non-adherence
(p=0.02) such that the associations between both once-daily
regimens and self-report non-adherence were attenuated over
follow up when compared to the standard of care regimen.
Specifically, at month 1, when compared to the standard of care
regimen, the once-daily PI-based regimen (parameter est.=
20.24, p,0.01) and the one daily NNRTI/NRTIs regimen
(parameter est.=20.16, p=0.01) were both significantly associ-
ated with lower non-adherence than standard of care. However,
by month 10, the once-daily PI-based regimen (parameter est.=
20.09, p=0.13) was no longer associated with non-adherence, but
the once daily NNRTI/NRTIs regimen remained associated with
lower non-adherence (parameter est.=20.16, p,0.01). By the
end of follow up, neither once-daily regimen was significantly
associated with non-adherence (p.0.05) when compared to the
standard-of-care regimen, as the level of non-adherence for the PI-
based regimen increased at a greater slope than the standard of
care regimen throughout the follow-up. The once daily NNRTI/
NRTIs regimen also increased in non-adherence, but at a similar
rate as standard of care, thus continuing to have lower non-
adherence than the standard of care.
Predictors of time to treatment failure
Table 4 includes risk factors for time to treatment failure in four
different approaches. The first set of models (unadjusted analyses)
consists of unadjusted analyses. Next, we built a model with the
psychosocial and demographic variables together, but not the non-
adherence measures, then models including pill count non-
adherence or self-report non-adherence, respectively.
Unadjusted analyses. In the first, unadjusted set of analyses,
lower scores on both QOL subscales, specific region (being from
the U.S. compared to other regions), lower levels of satisfaction
with social support, and both non-adherence measures were
associated with higher hazard of treatment failure within the first
72 weeks of follow-up. The association between age and non-
adherence was marginally significant (p=.07).
Multivariable analyses with psychosocial variables. In
the second approach, which included the psychosocial and
demographic variables, but not non-adherence measures, lower
QOL health scores, younger age (,25 and 25–30 versus .=45),
and specific regions (being from the U.S. compared to other
regions) remained having higher hazard of treatment failure within
the first 72 weeks of follow-up.
Multivariable model adjusting for pill-count
nonadherence. Lower QOL health scores, younger age (,25
and 25–30 versus .=45), region (being from the U.S. compared
to other regions), and having missed any pills via pill count were
associated with higher hazard of treatment failure within first 72
weeks of follow-up. Because pill-count non-adherence is a
categorical variable, survival curves can be graphically portrayed
for time to treatment failure, stratified by adherent versus non-
adherent. This is depicted in Figure 1.
Multivariable model adjusting for self-report non-
adherence. Lower QOL health scores, younger age (,25 and
25–30 versus .=45), region (being from the U.S. compared to
Latin America and Asia), and higher self-report non-adherence
scores were associated with higher hazard of treatment failure
within the first 72 weeks of follow-up.
Discussion
With ART as a transformative treatment for HIV for over 20
years, an emphasis of refining treatment regimens is on simplifying
patient burden with respect to dosing, whilst making ART
available globally. Although one might expect that once a day
regimens would be easier for adherence versus more frequent
Adherence in ACTG A5175/PEARLS Study
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middle-income countries. With respect to efficacy, the primary
outcome of the PEARLS study showed noninferiority of a once-
daily NNRTI/NRTIs regimen compared to standard of care. The
present study follows up on that finding, revealing that overall both
once-daily regimens generally had lower pill-count and self-report
non-adherence than the standard of care twice a day dosing. For
example, according to pill-count, these two regimens had 28 and
47 percent lower odds of non-adherence when averaged over
follow up. Note that the PI-based regimen was shown in the
primary outcome trial to be inferior to standard of care, and hence
the lower non-adherence in the PI-based regimen compared to
standard of care suggests that the primary inferiority finding was
not due to poor adherence but instead worse virologic potency. Pill
count assessed non-adherence increased over time, and this
change over time did not vary by regimen: for pill-count both
once-daily regimens had lower non-adherence than standard of
care. Self-report non-adherence also increased over time as a main
effect, but its association with regimen did change with time. For
both once-daily regimens compared to the standard of care
regimen, the associations with lower self-report non-adherence
waned with time. It is unclear as to why this pattern of results
occurred. Examining the slopes of self-report non-adherence, all
groups increased non-adherence over time, with the PI-based
regimen having the fastest rate of worsening adherence.
Additionally, the standard of care regimen also had increased risk
for safety events in the primary trial, and this also could have
contributed to higher self-reported non-adherence as time went
Table 2. Longitudinal Bivariate Predictors of Non-Adherence (Missed any pills since last visit)
1,2.
Pill Count Self Report
OR 95% CI p-value Parameter Estimate 95% CI p-value
Regimen ,0.01 ,0.01
1-once daily PI+ NRTIs: ATV+DDI+FTC 0.72 (0.60, 0.86) ,0.01 20.16 (20.27, 20.05) ,0.01
2-once daily NNRTI + NRTIs EFV+FTC-TDF 0.53 (0.44, 0.63) ,0.01 20.16 (20.27, 20.06) ,0.01
3-standard of care: EFV+3TC-ZDV 1.00 0.00 -
Time (Month) 1.05 (1.04, 1.06) ,0.01 0.003 (20.002, 0.01) 0.23
QOL Subscales
QOL_health 0.95 (0.93, 0.98) ,0.01 20.04 (20.06, 20.03) ,0.01
QOL_mental 0.97 (0.93, 1.01) 0.20 20.05 (20.08, 20.02) ,0.01
Age 0.23 0.49
,25 1.37 (1.00, 1.88) - 0.13 (20.06, 0.32) -
252,30 1.16 (0.90, 1.51) - 0.10 (20.05, 0.26) -
302,35 1.08 (0.84, 1.38) - 0.05 (20.10, 0.20) -
352,40 1.24 (0.97, 1.61) - 0.09 (20.06, 0.25) -
402,45 1.01 (0.76, 1.33) - 20.01 (20.18, 0.15) -
.=45 1.00 0.00
Female Sex 0.74 (0.64, 0.86) ,0.01 20.23 (20.32, 20.14) ,0.01
Region ,0.01 ,0.01
Latin America/Caribbean 0.92 (0.75, 1.14) 0.46 20.21 (20.35, 20.06) ,0.01
Asia 0.78 (0.61, 0.98) 0.03 20.38 (20.53, 20.23) ,0.01
Africa 0.52 (0.42, 0.64) ,0.01 20.55 (20.69, 20.40) ,0.01
United States 1.00 0.00
Binge Alcohol Use (at least weekly) 1.35 (1.09, 1.68) ,0.01 0.13 (20.02, 0.28) 0.08
Soft Drug Use, past month 1.48 (1.05, 2.08) 0.02 0.53 (0.30, 0.76) ,0.01
Hard Drug Use, past month 2.85 (1.74, 4.66) ,0.01 0.92 (0.54, 1.31) ,0.01
Any Unprotected Sex, past month 1.48 (1.13, 1.95) ,0.01 0.19 (20.002, 0.38) 0.05
Satisfaction with Social Support 0.23 ,0.01
Very satisfied 0.85 (0.71, 1.02) - 20.21 (20.34, 20.09) ,0.01
Somewhat satisfied 0.87 (0.72, 1.06) - 20.16 (20.29, 20.02) 0.02
Very/somewhat dissatisfied 1.00 0.00
1All models include random intercept (covariance=unstructured).
2All models include "month of follow up" as a main effect.
Table Legend:
Regimen 1: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.
Regimen 2: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-tenofovir-DF.
Regimen 3: Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.
QOL_health: general health perceptions.
QOL_mental: mental health.
doi:10.1371/journal.pone.0104178.t002
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and not the pill-count outcome, so this should be interpreted as
preliminary.
In the present study, after accounting for regimen, both pill-
count and self-report non-adherence was associated with earlier
treatment failure. Taken together, these data would suggest that
once-a-day dosing, in the context of similar efficacy, may result in
lower non-adherence and better outcomes in individuals receiving
ART for HIV.
Additional findings from this analysis revealed that certain
psychosocial variables were associated with non-adherence in
multivariable models. These findings are generally consistent with
existing studies of adherence in global settings referenced above,
highlighting the importance of the psychosocial context of health
behavior in multiple settings. For example, lower quality of life
mental health scores were associated with higher non-adherence in
the self-report bivariate and multivariable models. This is a
potentially modifiable variable through counseling or referrals in
that providers can potentially help patients address such problems.
Lower general health perceptions were associated with higher non-
adherence in all models of adherence, and all models of time to
treatment failure. This suggests that patients who feel worse,
potentially due to higher symptom side-effect profiles, or different
comorbidities, seem to have worse adherence, and worse
outcomes. With the findings that early treatment of HIV may
result in lower transmissions [2], it would be important to study
adherence in those whose health status and perceived health may
be high, as one study in Uganda found that those who started
ARVs at higher CD4 counts were more likely to have treatment
interruptions and detectable virus at three months after initiation
[21]. Female sex was associated with lower levels of non-adherence
in the two bivariate models, and with self-report adherence in the
multivariable model. Future studies should explore why women, in
this context, might fare better than men in an ART treatment trial.
The two youngest age groups had a higher hazard of treatment
failure. There may be a need for additional interventions for
younger individuals living with HIV/AIDS as others have
documented that ART adherence can be a problem in adolescents
[22]. Lastly, there may be various reasons for the findings related
to region, including cultural factors related to demand character-
istics (e.g. wanting to show that they are complying with study
procedures, social desirability), distribution of demographic
characteristics such as proportion of men and women, and clinical
characteristics at baseline due to country specific treatment
guidelines.
Table 3. Longitudinal Multivariable Predictors of Non-Adherence
1.
Pill Count Self Report
aOR 95% CI p-value Parameter Estimate 95% CI p-value
Month 1.06 (1.05, 1.06) ,0.01 0.008 (0.002, 0.01) ,0.01
QOL Subscales
QOL_health 0.95 (0.93, 0.97) ,0.01 20.04 (20.05, 20.02) ,0.01
QOL_mental — — — 20.03 (20.06, 20.00) 0.04
Treatment ,0.01 ,0.01
1-once daily PI + NRTIs: ATV+DDI+FTC 0.72 (0.61, 0.86) ,0.01 20.14 (20.25, 20.04) ,0.01
2-once daily NNRTI + NRTIs: EFV+FTC-TDF 0.52 (0.43, 0.62) ,0.01 20.16 (20.27, 20.05) ,0.01
3-standard of care: EFV+3TC-ZDV 1.00 0.00
Female Sex 0.88 (0.75, 1.02) 0.09 20.12 (20.21, 20.03) 0.01
Region ,0.01 ,0.01
Latin America/Caribbean 0.97 (0.76, 1.23) 0.79 20.08 (20.23, 0.07) 0.31
Asia 0.87 (0.67, 1.12) 0.28 20.21 (20.37, 20.05) 0.01
Africa 0.55 (0.43, 0.71) ,0.01 20.39 (20.55, 20.24) ,0.01
United States 1.00 0.00
Binge Alcohol Use (at least weekly) 1.21 (0.97, 1.50) 0.09 0.03 (20.12, 0.18) 0.74
Soft Drug Use, past month 1.11 (0.78, 1.58) 0.57 0.28 (0.05, 0.52) 0.02
Hard Drug Use, past month 2.16 (1.28, 3.62) ,0.01 0.70 (0.29, 1.11) ,0.01
Any Unprotected Sex, past month 1.47 (1.12, 1.93) ,0.01 0.15 (20.03, 0.34) 0.12
Satisfaction with Social Support — 0.07
Very satisfied — — — 20.15 (20.27, 20.02) —
Somewhat satisfied — — — 20.15 (20.29, 20.01) —
Very/somewhat dissatisfied — 0.00
1Model includes random intercept (covariance=unstructured).
Table Legend:
QOL_health: general health perceptions.
QOL_mental: mental health.
Treatment 1: Once daily protease inhibitor + nucleoside reverse transcriptase inhibitors: atazanavir + didanosine-EC and emtricitabine.
Treatment 2: Once daily non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors: efavirenz + co-formulated emtricitabine-
tenofovir-DF.
Treatment 3: Standard of care: efavirenz plus co-formulated lamivudine-zidovudine.
doi:10.1371/journal.pone.0104178.t003
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PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104178There are several limitations of the present study to note. First,
although both non-adherence outcomes were associated with time
to treatment failure, they are both imperfect measures. Self-report,
particularly in the context of a treatment trial where those at high
risk for non-adherence are not necessarily enrolled, may be
influenced by demand characteristics, specifically social desirability
when receiving free ART. We attempted to reduce this as much as
possible using the principal components analysis to attain a non-
adherence latent variable [18]. Pill count non-adherence is also
imperfect in that subjects can remove pills from containers when
returning to the clinic. Second, non-adherence, predictors of non-
adherence, and time to failure may be different in the context of a
clinical trial than in clinical care. When this study started, for
example, access to ART was not widely available in all of the study
settings, and hence there was high motivation to enter the study
and stay in it. This may result in other demand characteristics
relating to adherence. Now that ART is more widely available in
global settings, particularly for those with advanced disease, it will
be important to continue to study psychosocial predictors of
adherence related to adherence as the epidemic and its treatment
changes.
The primary finding that simplified regimens may facilitate
adherence to ART is an important one for resource poor settings
in that there may be a wide range of other barriers to adherence
ranging from work schedule to nutritional status, and variables
related to quality of life. In some locations, there are a limited
number of regimens available from government sponsored
programs, and hence as regimens are selected, ones with fewer
requirements may be easier for patients to adhere to and therefore
avoid treatment switches. The present study showed that in diverse
settings, generally the simplified once a day dosing regimens had
better adherence than the twice-a-day dosing over and above the
effects of other important psychosocial variables, some of which
also had independent effects on adherence. As newer agents are
developed, the continued introduction of simplified regimens may
facilitate better adherence and outcomes.
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Figure 1. ACTG A5175/Pearls trial – Survival probability estimate from randomization to treatment failure by pill count non-
adherence (solid line = did not miss any pills; dashed line = missed any pills).
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